Full Text Journal Articles by
Author Francesca R Mauro

Advertisement

Find full text journal articles






Efficacy of recombinant erythropoietin in autoimmune haemolytic anaemia: a multicentre international study.

Bruno Fattizzo, Marc Michel, Anna Zaninoni, Juri Giannotta, Stephanie Guillet, Henrik Frederiksen, Josephine M I Vos, Francesca R Mauro, Bernd Jilma, Andrea Patriarca, Francesco Zaja, Anita Hill, Sigbiørn Berentsen, Wilma Barcellini,

Haematologica (Haematologica)
[2020, :]

Cited: 0 times

View full text PDF listing >>



International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia.

Adalgisa Condoluci, Lodovico Terzi di Bergamo, Petra Langerbeins, Manuela A Hoechstetter, Carmen D Herling, Lorenzo De Paoli, Julio Delgado, Kari G Rabe, Massimo Gentile, Michael Doubek, Francesca R Mauro, Giorgia Chiodin, Mattias Mattsson, Jasmin Bahlo, Giovanna Cutrona, Jana Kotaskova, Clara Deambrogi, Karin E Smedby, Valeria Spina, Alessio Bruscaggin, Wei Wu, Riccardo Moia, Elena Bianchi, Bernhard Gerber, Emanuele Zucca, Silke Gillessen, Michele Ghielmini, Franco Cavalli, Georg Stussi, Mark A Hess, Tycho S Baumann, Antonino Neri, Manlio Ferrarini, Richard Rosenquist, Francesco Forconi, Robin Foà, Sarka Pospisilova, Fortunato Morabito, Stephan Stilgenbauer, Hartmut Döhner, Sameer A Parikh, William G Wierda, Emili Montserrat, Gianluca Gaidano, Michael Hallek, Davide Rossi,

Most patients with chronic lymphocytic leukemia (CLL) are diagnosed with early-stage disease and managed with active surveillance. The individual course of patients with early-stage CLL is heterogeneous, and their probability of needing treatment is hardly anticipated at diagnosis. We aimed at developing an international prognostic score to predict time to ... Read more >>

Blood (Blood)
[2020, 135(21):1859-1869]

Cited: 0 times

View full text PDF listing >>



Advertisement

Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group.

Yair Herishanu, Adir Shaulov, Riva Fineman, Sandra Bašić-Kinda, Ariel Aviv, Ewa Wasik-Szczepanek, Ozren Jaksic, Mihnea Zdrenghea, Uri Greenbaum, Inga Mandac, Martin Simkovic, Marta Morawska, Ohad Benjamini, Martin Spacek, Anatoly Nemets, Osnat Bairey, Livio Trentin, Rosa Ruchlemer, Luca Laurenti, Oana Stanca Ciocan, Michael Doubek, Lev Shvidel, Nagib Dali, Fátima Mirás, Anne De Meûter, Maria Dimou, Francesca R Mauro, Marta Coscia, Horia Bumbea, Róbert Szász, Tamar Tadmor, Odit Gutwein, Massimo Gentile, Lydia Scarfò, Alessandra Tedeschi, Paolo Sportoletti, Eva Gimeno Vázquez, Juan Marquet, Sarit Assouline, Maria Papaioannou, Andrei Braester, Luciano Levato, Michael Gregor, Gian M Rigolin, Javier Loscertales, Angeles Medina Perez, Marten R Nijziel, Viola M Popov, Rosa Collado, Irma Slavutsky, Gilad Itchaki, Shimrit Ringelstein, Neta Goldschmidt, Chava Perry, Shai Levi, Aaron Polliack, Paolo Ghia,

In recent years, considerable progress has been made in frontline therapy for elderly/physically unfit patients with CLL. The combination of obinutuzumab and chlorambucil (O-Clb) has been shown to prolong progression free survival (PFS, median PFS-31.5 months) and overall survival (OS) compared to chlorambucil alone. More recently, obinutuzumab given in combination with ... Read more >>

Am. J. Hematol. (American journal of hematology)
[2020, 95(6):604-611]

Cited: 0 times

View full text PDF listing >>



Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations.

Sara Raponi, Caterina Ilari, Irene Della Starza, Luca V Cappelli, Luciana Cafforio, Alfonso Piciocchi, Valentina Arena, Paola Mariglia, Francesca R Mauro, Massimo Gentile, Giovanna Cutrona, Riccardo Moia, Chiara Favini, Fortunato Morabito, Davide Rossi, Gianluca Gaidano, Anna Guarini, Ilaria Del Giudice, Robin Foà,

In chronic lymphocytic leukaemia (CLL), caution is warranted regarding the clinical implications of immunoglobulin variable heavy chain region (IGHV) rearrangements with a 'borderline' (BL) percentage of mutations (i.e. 97-97·9% IGHV identity). We analysed the IGHV mutational status in 759 untreated CLL patients (cohort 1). BL-CLL (n = 36, 5%) showed a time ... Read more >>

Br. J. Haematol. (British journal of haematology)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia.

Fary Diop, Riccardo Moia, Chiara Favini, Elisa Spaccarotella, Lorenzo De Paoli, Alessio Bruscaggin, Valeria Spina, Lodovico Terzi-di-Bergamo, Francesca Arruga, Chiara Tarantelli, Clara Deambrogi, Silvia Rasi, Ramesh Adhinaveni, Andrea Patriarca, Simone Favini, Sruthi Sagiraju, Clive Jabangwe, Ahad A Kodipad, Denise Peroni, Francesca R Mauro, Ilaria Del Giudice, Francesco Forconi, Agostino Cortelezzi, Francesco Zaja, Riccardo Bomben, Francesca Maria Rossi, Carlo Visco, Annalisa Chiarenza, Gian Matteo Rigolin, Roberto Marasca, Marta Coscia, Omar Perbellini, Alessandra Tedeschi, Luca Laurenti, Marina Motta, David Donaldson, Phil Weir, Ken Mills, Patrick Thornton, Sarah Lawless, Francesco Bertoni, Giovanni Del Poeta, Antonio Cuneo, Antonia Follenzi, Valter Gattei, Renzo Luciano Boldorini, Mark Catherwood, Silvia Deaglio, Robin Foà, Gianluca Gaidano, Davide Rossi,

BIRC3 is a recurrently mutated gene in chronic lymphocytic leukemia (CLL) but the functional implications of BIRC3 mutations are largely unexplored. Furthermore, little is known about the prognostic impact of BIRC3 mutations in CLL cohorts homogeneously treated with first-line fludarabine, cyclophosphamide, and rituximab (FCR). By immunoblotting analysis, we showed that ... Read more >>

Haematologica (Haematologica)
[2020, 105(2):448-456]

Cited: 1 time

View full text PDF listing >>



High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2).

Francesca R Mauro, Stefano Molica, Stefano Soddu, Fiorella Ilariucci, Marta Coscia, Francesco Zaja, Emanuele Angelucci, Francesca Re, Anna Marina Liberati, Alessandra Tedeschi, Gianluigi Reda, Daniela Pietrasanta, Alessandro Gozzetti, Roberta Battistini, Giovanni Del Poeta, Caterina Musolino, Mauro Nanni, Alfonso Piciocchi, Marco Vignetti, Antonino Neri, Francesco Albano, Antonio Cuneo, Ilaria Del Giudice, Irene Della Starza, Maria Stefania De Propris, Sara Raponi, Anna R Guarini, Robin Foà,

Haematologica (Haematologica)
[2020, :]

Cited: 0 times

View full text PDF listing >>



A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia.

Andrea Visentin, Marina Deodato, Francesca R Mauro, Francesco Autore, Gianluigi Reda, Candida Vitale, Stefano Molica, Gian Matteo Rigolin, Francesco Piazza, Laura Cesini, Alessandra Tedeschi, Luca Laurenti, Ramona Cassin, Marta Coscia, Antonio Cuneo, Robin Foà, Gianpietro Semenzato, Livio Trentin,

Hematol Oncol (Hematological oncology)
[2019, 37(4):508-512]

Cited: 0 times

View full text PDF listing >>



Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience.

Idanna Innocenti, Francesca Morelli, Francesco Autore, Alfonso Piciocchi, Annamaria Frustaci, Francesca R Mauro, Luana Schiattone, Livio Trentin, Giovanni Del Poeta, Gianluigi Reda, Gian M Rigolin, Adalberto Ibatici, Stefania Ciolli, Marta Coscia, Paolo Sportoletti, Roberta Murru, Luciano Levato, Massimo Gentile, Giovanni D'Arena, Dimitar G Efremov, Alessandra Tedeschi, Lydia Scarfò, Antonio Cuneo, Robin Foà, Luca Laurenti,

Br. J. Haematol. (British journal of haematology)
[2019, 187(1):e8-e11]

Cited: 1 time

View full text PDF listing >>



Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia.

Michael Steurer, Marco Montillo, Lydia Scarfò, Francesca R Mauro, Johannes Andel, Sophie Wildner, Livio Trentin, Ann Janssens, Sonja Burgstaller, Anna Frömming, Thomas Dümmler, Kai Riecke, Matthias Baumann, Diana Beyer, Stéphanie Vauléon, Paolo Ghia, Robin Foà, Federico Caligaris-Cappio, Marco Gobbi,

Olaptesed pegol (NOX-A12) is a pegylated structured L-oligoribonucleotide that binds and neutralizes CXCL12, a chemokine tightly regulating the life cycle of chronic lymphocytic leukemia cells. The resulting inhibition of CXCR4 and CXCR7 signaling reduces the protective activity of the bone marrow and lymph node microenvironment. CXCL12 inhibition mobilizes chronic lymphocytic ... Read more >>

Haematologica (Haematologica)
[2019, 104(10):2053-2060]

Cited: 0 times

View full text PDF listing >>



Unravelling the suboptimal response of TP53-mutated chronic lymphocytic leukaemia to ibrutinib.

Anna Guarini, Nadia Peragine, Monica Messina, Marilisa Marinelli, Caterina Ilari, Luciana Cafforio, Sara Raponi, Silvia Bonina, Paola Mariglia, Francesca R Mauro, Gianluca Gaidano, Ilaria Del Giudice, Robin Foà,

TP53-disrupted chronic lymphocytic leukaemia (CLL) patients show a suboptimal long-term response to ibrutinib. We hereby report that ibrutinib-induced in vitro apoptosis and proliferation inhibition were significantly lower in TP53-mutated (TP53-M) CLL cells compared to TP53 wild-type cells. Contrariwise, venetoclax effectively killed TP53-M cells. Gene expression profile analysis of TP53-M cells revealed a ... Read more >>

Br. J. Haematol. (British journal of haematology)
[2019, 184(3):392-396]

Cited: 1 time

View full text PDF listing >>



Balancing efficacy and toxicity of targeted agents currently used for the treatment of patients with chronic lymphocytic leukemia.

Francesca R Mauro, Maria D Caputo, Serena Rosati, Sara Pepe, Daniela De Benedittis, Maria L De Luca, Robin Foà,

INTRODUCTION:In recent years, innovative mechanism-based drugs have enriched the therapeutic armamentarium for patients with chronic lymphocytic leukemia (CLL) and are widely used in the clinical practice. These small molecules targeting the B-cell receptor signaling pathway and the BCL-2 anti-apoptotic protein offer new chemo-free options to both unfit patients and high-risk ... Read more >>

Expert Rev Hematol (Expert review of hematology)
[2018, 11(8):601-611]

Cited: 1 time

View full text PDF listing >>



Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease.

Sara Raponi, Ilaria Del Giudice, Caterina Ilari, Luciana Cafforio, Monica Messina, Luca V Cappelli, Silvia Bonina, Alfonso Piciocchi, Marilisa Marinelli, Nadia Peragine, Paola Mariglia, Francesca R Mauro, Gian M Rigolin, Francesca Rossi, Riccardo Bomben, Michele Dal Bo, Giovanni Del Poeta, Fary Diop, Chiara Favini, Davide Rossi, Gianluca Gaidano, Antonio Cuneo, Valter Gattei, Anna Guarini, Robin Foá,

Br. J. Haematol. (British journal of haematology)
[2019, 185(1):156-159]

Cited: 0 times

View full text PDF listing >>



In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics.

Gian Matteo Rigolin, Elena Saccenti, Emanuele Guardalben, Maurizio Cavallari, Luca Formigaro, Barbara Zagatti, Andrea Visentin, Francesca R Mauro, Enrico Lista, Cristian Bassi, Laura Lupini, Francesca Maria Quaglia, Antonio Urso, Maria Antonella Bardi, Laura Bonaldi, Eleonora Volta, Elisa Tammiso, Caterina Ilari, Luciana Cafforio, Aurora Melandri, Francesco Cavazzini, Massimo Negrini, Gianpietro Semenzato, Livio Trentin, Robin Foà, Antonio Cuneo,

Complex karyotype (CK) is a negative prognostic factor in chronic lymphocytic leukaemia (CLL). However, CK is a heterogeneous cytogenetic category. Unbalanced rearrangements were present in 73·3% of 90 CLL patients with CK (i.e. ≥3 chromosome aberrations in the same clone), and were associated with a shorter overall survival (P = 0·025) and ... Read more >>

Br. J. Haematol. (British journal of haematology)
[2018, 181(2):229-233]

Cited: 2 times

View full text PDF listing >>



Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed cases.

Massimo Gentile, Tait D Shanafelt, Francesca R Mauro, Luca Laurenti, Davide Rossi, Stefano Molica, Iolanda Vincelli, Giovanna Cutrona, Giuseppina Uccello, Sara Pepe, Ernesto Vigna, Giovanni Tripepi, Kari G Chaffee, Sameer A Parikh, Sabrina Bossio, Anna Grazia Recchia, Idanna Innocenti, Raffaella Pasquale, Antonino Neri, Manlio Ferrarini, Gianluca Gaidano, Robin Foà, Fortunato Morabito,

Am. J. Hematol. (American journal of hematology)
[2018, 93(2):E35-E37]

Cited: 5 times

View full text PDF listing >>



Venetoclax: a chance for patients with chronic lymphocytic leukaemia previously treated with ibrutinib.

Francesca R Mauro, Robin Foà,

Lancet Oncol. (The Lancet. Oncology)
[2018, 19(1):7-8]

Cited: 0 times

View full text PDF listing >>



Clinical relevance of silent red blood cell autoantibodies.

Francesca R Mauro, Fabio Trastulli, Cristiano Alessandri, Guido Valesini, Gianluca Giovannetti, Costantino Riemma, Marika Porrazzo, Sara Pepe, Gioia Colafigli, Maria D Caputo, Maria S De Propris, Anna R Guarini, Gabriella Girelli, Serelina Coluzzi, Robin Foà,

Haematologica (Haematologica)
[2017, 102(12):e473-e475]

Cited: 4 times

View full text PDF listing >>



Clinical relevance of hypogammaglobulinemia, clinical and biologic variables on the infection risk and outcome of patients with stage A chronic lymphocytic leukemia.

Francesca R Mauro, Fortunato Morabito, Iolanda D Vincelli, Luigi Petrucci, Melissa Campanelli, Adriano Salaroli, Giuseppina Uccello, Annamaria Petrungaro, Francesca Ronco, Sara Raponi, Mauro Nanni, Antonino Neri, Manlio Ferrarini, Anna R Guarini, Robin Foà, Massimo Gentile,

The prognostic effect of hypogammaglobulinemia (HGG), clinical and biologic characteristics on the infection risk and outcome has been retrospectively analyzed in 899 patients with stage A chronic lymphocytic leukemia (CLL). Low levels of IgG were recorded in 19.9% of patients at presentation, low levels of IgM and/or IgA in 10.4% ... Read more >>

Leuk. Res. (Leukemia research)
[2017, 57:65-71]

Cited: 1 time

View full text PDF listing >>



Another treatment option for relapsed or refractory chronic lymphocytic leukaemia.

Francesca R Mauro,

Lancet Oncol. (The Lancet. Oncology)
[2017, 18(3):270-271]

Cited: 1 time

View full text PDF listing >>



Management of elderly and unfit patients with chronic lymphocytic leukemia.

Francesca R Mauro, Adriano Salaroli, Maria D Caputo, Gioia Colafigli, Luigi Petrucci, Melissa Campanelli, Antonietta Ferretti, Anna R Guarini, Robin Foà,

About 75% of patients with chronic lymphocytic leukemia (CLL) are more than 65 years at the time of diagnosis. Treatment of the elderly remains complicated due to multiple factors, such as comorbidities, decline in functional reserve and fitness. Since chronological age by itself cannot properly predict life expectancy and treatment tolerance, ... Read more >>

Expert Rev Hematol (Expert review of hematology)
[2016, 9(12):1165-1175]

Cited: 1 time

View full text PDF listing >>



Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial.

Francesca R Mauro, Angelo M Carella, Stefano Molica, Francesca Paoloni, Anna M Liberati, Francesco Zaja, Valeria Belsito, Agostino Cortellezzi, Rita Rizzi, Patrizia Tosi, Mauro Spriano, Antonietta Ferretti, Mauro Nanni, Marilisa Marinelli, Maria S De Propris, Sonia M Orlando, Marco Vignetti, Antonio Cuneo, Anna R Guarini, Robin Foà,

The activity and safety of a regimen combining lenalidomide with fludarabine and cyclophosphamide (FC) was investigated in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Treatment consisted of six monthly courses of the FC regimen combined with 14 days of lenalidomide given at the starting dose of 2.5 mg during course ... Read more >>

Leuk. Lymphoma (Leukemia & lymphoma)
[2017, 58(7):1640-1647]

Cited: 6 times

View full text PDF listing >>



Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients.

Massimo Gentile, Tait D Shanafelt, Davide Rossi, Luca Laurenti, Francesca R Mauro, Stefano Molica, Giovanna Cutrona, Giuseppina Uccello, Melissa Campanelli, Ernesto Vigna, Giovanni Tripepi, Kari G Chaffee, Sameer A Parikh, Sabrina Bossio, Anna Grazia Recchia, Idanna Innocenti, Raffaella Pasquale, Antonino Neri, Manlio Ferrarini, Gianluca Gaidano, Robin Foà, Fortunato Morabito,

Blood (Blood)
[2016, 128(16):2093-2095]

Cited: 18 times

View full text PDF listing >>



Clinical characteristics and outcome of patients with autoimmune hemolytic anemia uniformly defined as primary by a diagnostic work-up.

Francesca R Mauro, Serelina Coluzzi, Francesca Paoloni, Fabio Trastulli, Daniele Armiento, Antonietta Ferretti, Gianluca Giovannetti, Gioia Colafigli, Matteo Molica, Ursula la Rocca, Maria S De Propris, Roberto Caronna, Giacomo Morano, Anna Guarini, Gabriella Girelli, Robin Foà,

Am. J. Hematol. (American journal of hematology)
[2016, 91(7):E319-20]

Cited: 0 times

View full text PDF listing >>



Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials.

Massimo Gentile, Katja Zirlik, Stefania Ciolli, Francesca R Mauro, Nicola Di Renzo, Lucia Mastrullo, Francesco Angrilli, Stefano Molica, Giovanni Tripepi, Annamaria Giordano, Francesco Di Raimondo, Carmine Selleri, Marta Coscia, Maurizio Musso, Lorella Orsucci, Donato Mannina, Angela Rago, Angela Giannotta, Felicetto Ferrara, Yair Herishanu, Lev Shvidel, Tamar Tadmor, Ilaria Scortechini, Fiorella Ilariucci, Roberta Murru, Attilio Guarini, Gerardo Musuraca, Giuseppe Mineo, Iolanda Vincelli, Annalisa Arcari, Giuseppe Tarantini, Giuseppe Caparrotti, Annalisa Chiarenza, Luciano Levato, Maria Rosaria Villa, Maria Rosaria De Paolis, Pier Luigi Zinzani, Aaron Polliack, Fortunato Morabito,

Recently, encouraging results in terms of safety and efficacy have been obtained using bendamustine-rituximab (BR) in untreated chronic lymphocytic leukaemia (CLL) patients enrolled in a phase II study. Here, we report a retrospective international multicenter study of CLL patients treated with BR as front-line therapy. The cohort included 279 patients ... Read more >>

Eur. J. Cancer (European journal of cancer (Oxford, England : 1990))
[2016, 60:154-165]

Cited: 8 times

View full text PDF listing >>



Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.

Davide Rossi, Lodovico Terzi-di-Bergamo, Lorenzo De Paoli, Michaela Cerri, Guido Ghilardi, Annalisa Chiarenza, Pietro Bulian, Carlo Visco, Francesca R Mauro, Fortunato Morabito, Agostino Cortelezzi, Francesco Zaja, Francesco Forconi, Luca Laurenti, Ilaria Del Giudice, Massimo Gentile, Iolanda Vincelli, Marina Motta, Marta Coscia, Gian Matteo Rigolin, Alessandra Tedeschi, Antonino Neri, Roberto Marasca, Omar Perbellini, Carol Moreno, Giovanni Del Poeta, Massimo Massaia, Pier Luigi Zinzani, Marco Montillo, Antonio Cuneo, Valter Gattei, Robin Foà, Gianluca Gaidano,

Fludarabine, cyclophosphamide, and rituximab (FCR) has represented a significant treatment advancement in chronic lymphocytic leukemia (CLL). In the new scenario of targeted agents, there is an increasing interest in identifying patients who gain the maximum benefit from FCR. In this observational multicenter retrospective analysis of 404 CLL patients receiving frontline ... Read more >>

Blood (Blood)
[2015, 126(16):1921-1924]

Cited: 80 times

View full text PDF listing >>



Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study.

Massimo Gentile, Giovanna Cutrona, Stefano Molica, Fiorella Ilariucci, Francesca R Mauro, Nicola Di Renzo, Francesco Di Raimondo, Iolanda Vincelli, Katia Todoerti, Serena Matis, Caterina Musolino, Sonia Fabris, Marta Lionetti, Luciano Levato, Simona Zupo, Francesco Angrilli, Ugo Consoli, Gianluca Festini, Giuseppe Longo, Agostino Cortelezzi, Pellegrino Musto, Massimo Federico, Antonino Neri, Manlio Ferrarini, Fortunato Morabito,

We performed an external and multicentric validation of the predictive value of abdominal computed tomography (aCT) on time to first treatment (TTFT) in early stage chronic lymphocytic leukemia (CLL) patients.aCT was performed at diagnosis in 181 Rai 0 patients enrolled in the O-CLL1-GISL trial (clinicaltrial.gov ID:NCT00917549).Fifty-five patients showed an abnormal ... Read more >>

Eur. J. Haematol. (European journal of haematology)
[2016, 96(1):36-45]

Cited: 2 times

View full text PDF listing >>



Advertisement

Disclaimer
1.2232 s